Dr. Riva will serve as the senior vice president and head of Gilead’s hematology and oncology therapeutic area, according to the report. He will also join the company’s executive committee.
In his 12 years at Basel, Switzerland-based Novartis, Dr. Riva led the development of more than 20 cancer compounds and oversaw the regulatory approvals of drugs for both solid and hematological malignancies.
More articles on supply chain:
Why driverless cars could magnify the organ donor shortage
Amazon’s newest endeavor: A floating warehouse
How ‘phantom inventory’ could be hurting your supply chain
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
